Related Experiment Videos
[Refractory psoriasis treatment with etanercept]
Laura Mahiques Santos1, Teresa Martínez-Menchón, José Luis Sánchez Carazo
1Servicio de Dermatología y Venereología, Hospital General Universitario de Valencia, Valencia, Spain. laura_mahiques@aedv.es
Medicina Clinica
|September 28, 2005
Summary
Etanercept effectively treats severe psoriasis, with 96% of patients showing improvement within 12 weeks. This psoriasis treatment was well-tolerated and showed sustained efficacy over 6 months.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Context:
- Psoriasis is a chronic inflammatory skin condition.
- Severe and refractory psoriasis poses significant treatment challenges.
- Tumor necrosis factor (TNF) plays a key role in psoriasis pathogenesis.
Purpose:
- To evaluate the efficacy and maintenance of etanercept in severe, refractory psoriasis.
- To assess the safety profile of etanercept in this patient population.
- To determine the time to relapse after etanercept treatment cessation.
Summary:
- An open-label trial included 22 patients with severe, refractory psoriasis.
- Patients received etanercept 50 mg/week subcutaneously for 6 months.
- Psoriasis Area and Severity Index (PASI) scores were monitored monthly.
Impact:
- 96% of patients achieved PASI improvement by week 12, sustained to week 24.
- Etanercept demonstrated good tolerability with no significant adverse reactions.
- The study suggests etanercept is a promising therapy for severe psoriasis, warranting further long-term studies.